Clinical Study

In Vivo Corneal Confocal Microscopy Detects Improvement of Corneal Nerve Parameters following Glycemic Control in Patients with Type 2 Diabetes

Table 1

Clinical characteristics of control subjects and patients with diabetes at baseline and one-year follow-up.

ParameterBaselineOne-year follow-up value
Control, Ia ()Diabetes, IIa ()Control, Ib ()Diabetes, IIb ()Ia versus IIaIb versus IaIIb versus IIa

Age, y54.4 ± 12.756.9 ± 14.755.3 ± 12.858.1 ± 14.60.488≤0.001≤0.001
Sex (M/F)6/618/14
Duration of diabetes, y11.2 ± 9.212.4 ± 9.0≤0.001
Weight, kg63.8 ± 7.471.0 ± 16.563.4 ± 8.170.1 ± 14.50.1550.6920.318
BMI, kg/m223.15 ± 2.4025.80 ± 4.7822.9 ± 2.2025.50 ± 4.140.0750.6310.328
SBP, mmHg122.3 ± 11.8137.8 ± 16.3122.8 ± 11.4133.3 ± 14.20.0050.5640.175
DBP, mmHg73.5 ± 5.682.6 ± 8.074.0 ± 5.581.3 ± 10.60.0010.5510.396
TC, mmol/L4.88 ± 0.674.52 ± 1.074.71 ± 0.594.59 ± 1.140.4070.2960.902
TG, mmol/L1.25 ± 0.561.94 ± 1.821.21 ± 0.511.78 ± 1.570.1770.8190.483
LDLC, mmol/L2.78 ± 0.642.69 ± 0.722.67 ± 0.612.56 ± 0.830.8840.4570.326
HDLC, mmol/L1.51 ± 0.281.22 ± 0.331.42 ± 0.281.30 ± 0.310.0080.1070.058
HbA1c, %5.36 ± 0.128.22 ± 1.675.38 ± 0.117.58 ± 1.47≤0.0010.2750.058
TCSS0.6 ± 0.75.2 ± 4.50.7 ± 0.75.4 ± 4.80.0010.6740.338
PMNCV, m/s50.20 ± 2.8444.67 ± 4.0749.34 ± 2.3643.43 ± 3.80≤0.0010.2010.496
TMNCV, m/s50.56 ± 3.1544.24 ± 4.6050.03 ± 2.3942.46 ± 4.76≤0.0010.3410.439
SPSNCV, m/s55.44 ± 3.9948.71 ± 7.3654.98 ± 3.2346.76 ± 7.20≤0.0010.4910.049
SSNCV, m/s53.69 ± 3.0548.34 ± 7.1852.63 ± 2.0044.92 ± 6.210.0170.1560.146
CNFD, n/mm229.31 ± 4.3118.71 ± 4.7328.29 ± 3.3819.12 ± 5.99≤0.0010.0930.643
CNBD, n/mm242.19 ± 13.9121.80 ± 14.6739.11 ± 18.1120.78 ± 12.980.0030.2790.667
CNFL, mm/mm217.96 ± 2.4011.81 ± 2.4617.15 ± 2.4411.63 ± 2.72≤0.0010.1910.737

Results are expressed as mean ± SD or counts for categorical variables. Independent-sample -test. Paired-sample t-test. test.